Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt Sells 700 Shares of Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 700 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the sale, the vice president now owns 10,149 shares of the company’s stock, valued at $402,103.38. This trade represents a 6.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN opened at $39.00 on Thursday. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $39.69. The firm has a market capitalization of $2.15 billion, a P/E ratio of 36.45 and a beta of 0.90. The company has a 50-day simple moving average of $37.04 and a 200-day simple moving average of $34.36.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The firm had revenue of $175.70 million for the quarter, compared to analyst estimates of $157.35 million. During the same quarter in the previous year, the firm posted ($0.29) EPS. The business’s revenue for the quarter was up 14.2% on a year-over-year basis. As a group, equities analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Barclays PLC raised its position in Supernus Pharmaceuticals by 88.3% in the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock valued at $3,393,000 after purchasing an additional 51,005 shares during the last quarter. Segall Bryant & Hamill LLC acquired a new position in Supernus Pharmaceuticals during the 3rd quarter worth about $791,000. Geode Capital Management LLC grew its holdings in Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after acquiring an additional 74,438 shares during the last quarter. Franklin Resources Inc. grew its holdings in Supernus Pharmaceuticals by 7.6% during the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock worth $987,000 after acquiring an additional 2,121 shares during the last quarter. Finally, Bank of Montreal Can increased its position in Supernus Pharmaceuticals by 1,508.0% in the 2nd quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company’s stock valued at $3,287,000 after acquiring an additional 109,088 shares in the last quarter.

Analysts Set New Price Targets

Several research firms have weighed in on SUPN. Cantor Fitzgerald began coverage on Supernus Pharmaceuticals in a report on Monday, January 6th. They set an “overweight” rating and a $57.00 target price on the stock. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.